Jason Witherington, GSK
Written by Jackie Howard Tuesday, 08 May 2012 11:05
Following a PhD in organic chemistry with Professor David Hodgson (Oxford), Jason Witherington moved to the US to complete a two year post doctoral position in bioorganic chemistry with Professors Amos B Smith and Ralph Hirschmann (University of Pennsylvania). He returned to the UK in 1997 to join Smithkline Beecham where he has been responsible for leading numerous programmes from lead identification to clinical candidate. He joined the ImmunoInflammation Centre of Excellence for drug discovery (IICEDD) within GSK at its inception and has assumed various positions, most recently as Head of Chemistry within the EpiNova Discovery Performance Unit (EpiNova DPU). He is co-author of over 100 peer reviewed articles and the current interest of his group is focussed on establishing the therapeutic potential of Epigenetic proteins.